Novo Nordisk’s SWOT analysis: diabetes giant faces fierce competition in GLP-1 stock battle September 1, 2025 by Finance On Earth Novo Nordisk’s Swot Analysis: Diabetes giants are a brutal competition in the GLP-1 Stock Battle